Credit: REUTERS/DIEGO VARAAug 25 (Reuters) - Sinovac Biotech Ltd SVA.O said on Tuesday it would help Indonesia's state-owned drugmaker Bio Farma produce in the country at least 40 million doses of its potential coronavirus vaccine before March 2021.
The U.S.-listed Chinese drugmaker has signed two agreements with Bio Farma for supply, local production and technology licensing of its vaccine candidate CoronaVac and the Indonesian company is conducting the late-stage study of the candidate.
Sinovac will continue to supply the bulk vaccine until the end of 2021 after March, it said in a statement.
There are no approved vaccine for COVID-19, with drugmakers and research organizations racing to develop a safe and effective vaccine that is seen as crucial to combat the pandemic.
CORRECTED-UPDATE 1-Indonesia books 50 mln coronavirus vaccine doses from Sinovac
FACTBOX- The race for a coronavirus vaccine
FACTBOX-U.S., UK spend billions to take lead in securing coronavirus vaccines
(Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)
((ankur.banerjee@thomsonreuters.com;; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132; Twitter: @AnkurBanerjee17;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
